Compare Corning Incorporated (GLW) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Corning Incorporated vs Neurocrine Biosciences Inc — how do they compare? Corning Incorporated trades at $156.61 (market cap $131.65B), while Neurocrine Biosciences Inc trades at $142.36 (market cap $14.36B). The key difference: Corning Incorporated is far larger — about 9.2× Neurocrine Biosciences Inc's market cap, and Corning Incorporated pays a 0.73% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Corning Incorporated for 36 Days and Neurocrine Biosciences Inc for 23 Days on average.
| GLW | NBIX | |
|---|---|---|
Market Cap | $131.65B | $14.36B |
Volume | 8,992,522 | 1,237,180 |
Sector | Technology | Health |
52-Week High | $255.79 | $185.50 |
52-Week Low | $78.03 | $123.10 |
Typical Hold Time | 36 Days | 23 Days |
Enterprise Value | $138.52B | $14.37B |
Dividend Yield | 0.73% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Corning (GLW) trades at $155.95, down 4.45% today amid a bearish technical outlook despite strong fundamentals. The company recently secured a significant $3B+ fiber supply agreement with AT&T, boosting its optical communications segment. GLW has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Analyst consensus remains positive with a $171.25 price target, though technical indicators show selling pressure with support at $149 and resistance at $158.
GLW presents a compelling long-term opportunity with strong revenue growth projections and strategic positioning in fiber optics for AI infrastructure. However, elevated valuation multiples (P/E 70.43) and ongoing patent litigation investigations pose near-term risks. The stock's current technical weakness may offer entry points for investors bullish on the company's fiber optic expansion and AI-driven connectivity demand.
Neurocrine Biosciences (NBIX) trades at $142.84, down 0.44% today, with strong fundamental performance including three consecutive quarterly earnings beats and robust profitability metrics. The stock shows bearish technical signals with resistance at $142-145, while maintaining excellent analyst support with 86% buy ratings and a $204 consensus target. Recent developments include pipeline advancements in Prader-Willi syndrome and executive appointments.
NBIX presents a compelling growth story with 20.9% net margins and expanding rare-disease portfolio, though faces execution risks as it diversifies beyond Ingrezza. The 43% upside to consensus target suggests significant potential, but investors must monitor pricing pressures and pipeline execution amid elevated valuation multiples.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Corning Incorporated
Corning Inc is a leader in materials science, specializing in the production of glass, ceramics and optical fiber. The firm supplies its products for a wide range of applications, from flat-panel displays in televisions to gasoline particulate filters in automobiles to optical fiber for broadband access, with a leading share in many of its end markets.
Read more on GLW →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
